SPORE IN LUNG CANCER

  • Kelly, Karen (PI)
  • Prochazka, Allan (PI)
  • Degregori, James V. (PI)
  • Pettijohn, David (PI)
  • Heasley, Lynn (PI)
  • Kane, Madeleine (PI)
  • Kazlauskas, Andrius (PI)
  • Drabkin, Harry A. (PI)
  • Baron, Anna (PI)
  • Keith, Robert (PI)
  • Merrick, Daniel Thomas (PI)
  • Kennedy, Timothy (PI)
  • Gemmill, Robert (PI)
  • Sclafani, Robert (PI)
  • Archer, Philip (PI)
  • Anderson, Marshall (PI)
  • Johnson, Gary (PI)
  • Stevens, James (PI)
  • Nemenoff, Raphael A. (PI)
  • Franklin, Wilbur (PI)
  • Miller, York (PI)
  • Bunn, Paul (PI)

Project: Research project

Description

The University of Colorado Cancer Center proposes to establish a
Specialized Program in Research Excellence (SPORE) in Lung cancer to expand
our understanding of the biology of lung cancer, to find new methods of
diagnosis, prevention and treatment and to serve as a regional, national
and international resource for the study of lung cancer. As a part of this
SPORE application we will conduct interrelating research projects, 8
clinical trials and support the 5 cores, the career development of 4 young
investigators and the recruitment of new investigators with special
research capabilities. Our research studies will focus on abnormalities in
growth factors pathways, changes in preneoplastic epithelium, and
abnormalities in lung cancer cells. This will include the study of
oncogenes and suppressor genes and methods to reverse abnormalities. We
will define intermediate markers associated with premalignant lesions and
whether these markers change in response to discontinuation of smoking,
retinoic acid therapy or other chemopreventive measures. We will study
agents which interfere with lung cancer signal transduction and determine
whether these are safe and useful for the treatment or prevention of lung
cancer. We will assess strategies to stop cigarette consumption with high
risk patients and the effects this has on intermediate markers. We will
establish new clinical protocols and conduct them alone or in collaboration
with other institutions. We will establish two "Banks" of tissues: 1) a
premalignant bank to include sputum and bronchial biopsies, bronchial
brushings, bronchial lavage and urine; 2) a malignant bank to include tumor
tissue, adjacent lung serum, and lymphocytes. These tissues will be
studied by our investigators and made available to the scientific community
on a peer-reviewed/availability basis. We will collaborate with other lung
cancer SPORES and lung cancer investigators to reach our goals.
StatusFinished
Effective start/end date9/30/924/30/19

Funding

  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health

Fingerprint

Tissue and Organ Procurement
Clinical Trials
Lung Neoplasms
Translational Medical Research
Bombesin
Sputum
Biomarkers
Hope
Specimen Handling
Neprilysin
Therapeutics
Peptides
Bronchoscopy
Neoplasms
Clinical Protocols
Pedigree
Genetic Predisposition to Disease
Research Personnel
Smoking Cessation
Secondary Prevention

ASJC

  • Medicine(all)